Table 2.
The representatives of clinical trials of drugs considered for repurposing in dementia.
| Drug | Approval | Mechanism of Action | Clinical Trials ID |
|---|---|---|---|
| Nilotinib | Chronic myelogenous leukemia | Tyrosine kinase inhibitor | NCT02947893 |
| Neflamapimod 1 | Antiarthritic/anti-inflammatory | p38 MAP kinase alpha inhibitor | NCT03402659 |
| Bexarotene | Anti-cancer | Retinoid X receptor agonist | NCT01782742 |
| Liraglutide | Anti-diabetic | Glucagon-like peptide 1 agonist | NCT01469351 |
| Rosiglitazone | Anti-diabetic | Peroxisome proliferator-activated receptor-γ agonist |
NCT00265148 NCT00428090 NCT00550420 |
| Nilvadipine | Anti-hypertensive | Calcium channel blocker | NCT02017340 |
| Candesartan | Anti-hypertensive | Angiotensin receptor blocker | NCT02646982 |
| Losartan | Anti-hypertensive | Angiotensin receptor blocker | EudraCT 2012–003641–15 |
| Losartan/amlodipine | Anti-hypertensive | Angiotensin receptor blocker/Calcium channel blocker | NCT05331144 |
| Rasagiline | Parkinson’s disease | Selective monoamine oxidase B inhibitor | NCT02359552 |
| Roflumilast | Severe chronic obstructive pulmonary disease | Phosphodiesterase 4 inhibitor | NCT02051335 NCT02079844 |
| Sildenafil | Erectile dysfunction, pulmonary arterial hypertension | Phosphodiesterase 5 inhibitor | NCT05039086 |
1 has been granted Fast Track status as a treatment for LBD by the FDA.